Showing 2961-2970 of 7016 results for "".
The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
https://reachmd.com/programs/cme/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.A Unique Look at the Current and Future Directions of Cancer Vaccines
https://reachmd.com/programs/project-oncology/a-unique-look-at-the-current-and-future-directions-of-cancer-vaccines/24503/Cancer vaccines have been of interest to oncologists for decades. Tune in.Primary Biliary Cholangitis: Shining Light on an "Invisible" Female Health Burden
https://reachmd.com/programs/cme/primary-biliary-cholangitis-shining-light-on-an-invisible-female-health-burden/36709/Review clinical features, diagnostic criteria, and treatment options for PBC, a chronic liver disease primarily affecting women over age 50.Effective Acute Pain Management Strategies for Adult Patients
https://reachmd.com/programs/clinicians-roundtable/effective-acute-pain-management-strategies-for-adult-patients/26726/Tune in to hear expert insights on the current approaches to treating acute pain in adults.IL-23 Inhibitors Show Broad PsA Control, with Important Gaps Remaining
https://reachmd.com/programs/living-rheum/il-23-inhibitors-show-broad-psa-control-with-important-gaps-remaining/54368/Pan-Coronavirus Vaccine Shows Broad Protection Against SARS-CoV-2 Variants
https://reachmd.com/programs/clinicians-roundtable/pan-coronavirus-vaccine-protection-sars-cov-2-variants/48838/Updates in MS Care: Key Topics at AAN 2026
https://reachmd.com/programs/neurofrontiers/aan-2026-key-topics-ms/54248/Hear from Dr. Aaron Miller as he shares important updates in multiple sclerosis (MS) at the 2026 American Academy of Neurology (AAN) Annual Meeting. Dr. Miller is the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and a Professor of Neurology at the Icahn SEarly Approaches to RAS Targeting: Efficacy Signals and Known Limitations
https://reachmd.com/programs/cme/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
https://reachmd.com/programs/heart-matters/attr-cm-trials-treatment-benefit/49050/Routes Reconsidered: A Case-Based Debate in SERD Selection
https://reachmd.com/programs/cme/routes-reconsidered-a-case-based-debate-in-serd-selection/39807/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.